-+ 0.00%
-+ 0.00%
-+ 0.00%

Teva's Final PEARL Study Data Confirm AJOVY's Sustained Migraine Prevention And Favorable Safety Over Two Years

Benzinga·06/23/2025 08:37:51
Listen to the news
  • Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2
  • Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period1,2
  • Injection adherence remained high throughout the study (~90%), while over 75% of patients completed the study duration1